Skip to main content
LIVN logo

LivaNova PLC (LIVN) Stock: Price, Forecast & Analyst Target

LivaNova PLC (LIVN) — MoonshotScore 88/100 (Exceptional band), calculated Oct 4, 2026. Price $75.07 (+0.50%), as of the Oct 2, 2026 trading session; market cap $4.12B.

Educational signal · not a buy or sell recommendation · How to read this

$75.07 +$0.37 (+0.50%) Market Cap $4.12B

LivaNova PLC · LIVN · NASDAQ

LivaNova PLC is a global medical device company focused on therapeutic solutions across cardiopulmonary, neuromodulation, and advanced circulatory support. The company sells its products through direct sales representatives and independent distributors.

Price as of Oct 2, 2026

Key Statistics

88 of 100

MoonshotScore v2 · LivaNova (LIVN)

Exceptional
Business Quality Elite (89)
Financial Safety Sound (75)
Valuation Fair (61)
Growth Durability Compounding (82)
Momentum Rising (76)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Elite quality, a strong balance sheet and durable growth, with no real weak spot — fairly priced, so not a bargain entry; the market is already moving on it. Business Quality: Elite; Financial Safety: Sound; Valuation: Fair; Growth Durability: Compounding; Momentum: Rising.

  • quarterly revenue $391M (Q2 FY2026, quarter ended Jun 2026)
  • EPS beat 8 of 8
  • Altman Z 2.25 · Piotroski F 8

Helping: business quality, balance-sheet strength, durable growth, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for LIVN (29 recorded, newest six shown)
RecordedScoreBand
85Exceptional
87Exceptional
88Exceptional
88Exceptional
88Exceptional
88Exceptional

The score was 88 in the stored Oct 3, 2026 snapshot and remains 88 in the current publication computed Oct 4, 2026 (0); the largest pillar moves were Growth Durability -1 and Momentum +1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged. This current publication is not yet represented in the immutable snapshot archive.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$75.07
Change on the day+0.50%
52-week range$48.82 – $85.76
Market capitalisation$4.12B
Price / earnings (trailing)21.76
Shares traded on the day528.5K

Price & events

Council Score · weighted blend of 2 available disciplines

Council score for LivaNova (LIVN): Bullish Lean

71/100 · A

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Growth Durability Strong
Momentum Moderate
Business Quality Strong
Financial Safety Moderate
Valuation Moderate

Legends Council

3 lenses, 3 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Unfavorable read

Read on: Oct 4, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Moderate
Revenue Growth Moderate
Debt/Equity Moderate
ROE Moderate
Gross Margin Strong

Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

One of these lenses reads this company less favourably than the MoonshotScore does: Moon AI lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Oct 4, 2026, except a card that shows its own read date.

Watch the LIVN film — every key number, told as a short cinematic story

~2 min · open the film

1 · What is it?

What is LivaNova (LIVN), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. LivaNova PLC (LIVN) is listed on NASDAQ. It employs 3,300 people and is led by Vladimir A. Makatsaria. In Q2 FY2026 it reported revenue of $391M and net income of $109M. The market values it at $4.12B.

2 · Latest results

What do the latest results show for LivaNova (LIVN)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of $391M. Against analyst estimates the company has EPS beat 8 of 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2026$391M$109M$1.93 (diluted)
Q1 FY2026$362M$22M$0.40 (diluted)
Q4 FY2025$361M$31M$0.57 (diluted)
Q3 FY2025$358M$27M$0.49 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for LivaNova (LIVN)?

Short answer

The MoonshotScore pillars rate business quality, balance-sheet strength, durable growth, positive momentum as strengths. The distress and quality screens read Altman Z 2.25 · Piotroski F 8. Trailing ratios: ROE 15.4% · ROA 7.1% · current ratio 1.45 · earnings yield 4.5% · free-cash-flow yield 3.5%.

4 · What to check next?

What should you watch next at LivaNova (LIVN)?

Short answer · as of

Current published price targets run low $76.00 · high $95.00 · consensus $88.50 · median $91.00 against a quoted price of $75.07 (as of Oct 2, 2026).

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does LivaNova compare with its peers?

Short answer

LivaNova's score ranks 4th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Inspire Medical Systems, Inc. (INSP) Same industry, near in market value$69.97 Oct 2, 2026$2.02B97 5-pillar Oct 4, 2026
Globus Medical, Inc. (GMED) Same industry, near in market value$75.60 Oct 2, 2026$10.2B96 5-pillar Oct 4, 2026
UFP Technologies, Inc. (UFPT) Same industry, near in market value$300.70 Oct 2, 2026$2.33B91 5-pillar Oct 4, 2026
LivaNova (LIVN) — this page$75.07$4.12B88
Insulet Corporation (PODD) Same industry, near in market value$131.69 Oct 2, 2026$9.12B83 5-pillar Oct 4, 2026
TransMedics Group, Inc. (TMDX) Same industry, near in market value$79.80 Oct 2, 2026$2.76B78 5-pillar Oct 4, 2026
Integer Holdings Corporation (ITGR) Same industry, near in market value$126.45 Oct 2, 2026$4.29B71 5-pillar Oct 4, 2026
Bruker Corporation (BRKR) Same industry, near in market value$63.24 Oct 2, 2026$9.63B59 5-pillar Oct 4, 2026
Scholar Rock Holding Corporation (SRRK) Named competitor$46.81 Oct 2, 2026$5.61B45 5-pillar Oct 4, 2026
Bio-Rad Laboratories, Inc. (BIO) Same industry, near in market value$369.14 Oct 2, 2026$9.94B40 5-pillar Oct 4, 2026
AxoGen, Inc. (AXGN) Same industry, near in market value$37.39 Oct 2, 2026$2.19B36 5-pillar Oct 4, 2026
Glaukos Corporation (GKOS) Same industry, near in market value$163.75 Oct 2, 2026$9.66B36 5-pillar Oct 4, 2026
Legend Biotech Corporation (LEGN) Named competitor$18.57 Oct 2, 2026$3.43B35 5-pillar Oct 4, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$76.00 – $95.00
Consensus target
$88.50
Median target
$91.00

Consensus record · Captured .

Measured against a quoted price of $75.07 (as of Oct 2, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 15, 2026

Transactions
51
Identified insiders
12
Purchases
0
Sales
6
Other transactions
45

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

What has been published about LivaNova (LIVN)?

Read these with our analysis →

LivaNova Stock: Key Questions Answered

These answers are editorial: 1 of these 9 answers is drawn from the LIVN research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for LIVN?

LIVN carries the MoonshotScore stated above — the Exceptional band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. LivaNova PLC is a global medical device company focused on therapeutic solutions across cardiopulmonary, neuromodulation, and advanced circulatory support.

Is LIVN a good stock to buy?

Stock Expert AI does not rate LIVN buy, sell or hold. LivaNova PLC carries a MoonshotScore, in the Exceptional band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the LIVN stock price today?

The last price recorded on this page for LivaNova PLC (LIVN) is $75.07, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the LIVN price target?

The analyst consensus price target for LivaNova PLC (LIVN) is $88.50 (range $76.00 to $95.00, median $91.00), per FMP data captured Oct 4, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What are the main risks for LIVN?

LivaNova PLC faces several risks inherent in the medical device industry. These include product liability claims and litigation related to medical devices, regulatory hurdles and delays in product approvals, intense competition from established medical device companies, and economic downturns affecting healthcare spending.

What are the key factors to evaluate for LIVN?

LivaNova PLC (LIVN) holds a MoonshotScore in the high range. P/E: 21.76x. Analysts target $88.50 (+18%). Adapting its product offerings to meet the specific needs of these markets will be crucial for success. Not financial advice.

How frequently does LIVN data refresh on this page?

LIVN's price is the last quote we recorded, from the Oct 2, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven LIVN's recent stock price performance?

LivaNova PLC (LIVN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product portfolio across multiple therapeutic areas. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider LIVN overvalued or undervalued right now?

LivaNova PLC (LIVN) trades at 21.76x earnings. Analysts target $88.50 (+18%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources — records for every figure on this page (22 figures)

The 22 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.

"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.

FMP — 14 facts from Financial Modeling Prep endpoint families

FMP facts used on this page
Fact IDFactValue as shownAs ofTierSource
px.lastLatest provided price$75.07FMPFinancial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-03T20:14:38.685Z.
px.changeChange on the day+0.50%FMPFinancial Modeling Prep (FMP) · quote
px.mcapMarket capitalisation$4.12BFMPFinancial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:01.000Z. Captured from FMP at 2026-10-03T20:14:37.739Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares.
px.change_absChange on the day, in dollars+$0.37FMPFinancial Modeling Prep (FMP) · quote
fin.q_revenueRevenue, Q2 FY2026$391MFMPFinancial Modeling Prep (FMP) · income statement (quarterly)
px.pePrice / earnings (trailing)21.76FMPFinancial Modeling Prep (FMP) · quote
px.volumeShares traded on the day528.5KFMPFinancial Modeling Prep (FMP) · quote
fin.q_incomeNet income, Q2 FY2026$109MFMPFinancial Modeling Prep (FMP) · income statement (quarterly)
fin.q_tableQuarterly income statement4 quarters through Q2 FY2026FMPFinancial Modeling Prep (FMP) · income statement (quarterly), as filed
earn.ptStored analyst price targetslow $76.00 · high $95.00 · consensus $88.50 · median $91.00FMPFinancial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied
earn.pt_rangeAnalyst price target, low to high$76.00 – $95.00FMPFinancial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied
earn.pt_consensusConsensus analyst price target$88.50FMPFinancial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied
earn.pt_medianMedian analyst price target$91.00FMPFinancial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied
own.insidersInsider transactions via FMP51 transactions · 0 purchases, 6 sales, 45 other transactions · 12 identified insiders · of the newest 100 records, those within the last 180 days, newest dated Sep 15, 2026FMPFinancial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

UNRECORDED — 6 facts from stored observations whose source was not recorded

UNRECORDED facts used on this page
Fact IDFactValue as shownAs ofTierSource
earn.historyReported versus estimated, recent quartersEPS beat 8 of 8UNRECORDEDStored earnings-history observation — Captured 2026-09-30 · Expired observation
fin.scoresDistress and quality screensAltman Z 2.25 · Piotroski F 8UNRECORDEDStored financial-scores observation — Captured 2026-10-03 · Expired observation
px.range5252-week range$48.82 – $85.76UNRECORDEDStored company-profile observation — Captured 2026-09-30
id.employeesEmployees3,300UNRECORDEDStored company-profile observation — Captured 2026-09-30
id.ceoChief executiveVladimir A. MakatsariaUNRECORDEDStored company-profile observation — Captured 2026-09-30
fin.ratiosReturn and yield ratios (trailing twelve months)ROE 15.4% · ROA 7.1% · current ratio 1.45 · earnings yield 4.5% · free-cash-flow yield 3.5%—UNRECORDEDStored key metrics — Date unknown

OURS — 2 facts from Stock Expert AI's own score and rank

OURS facts used on this page
Fact IDFactValue as shownAs ofTierSource
ours.moonshotMoonshotScore v288 of 100 · Exceptional · pillars 89 / 75 / 61 / 82 / 76OURSStock Expert AI MoonshotScore v2 engine
ours.moonshot_changeMoonshotScore movement88 (stored snapshot Oct 3, 2026) → 88 (current publication computed Oct 4, 2026) (0)OURSStock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive.
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.